The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study.
| dc.contributor.author | Ahmed, S | |
| dc.contributor.author | Harrity, C | |
| dc.contributor.author | Johnson, S | |
| dc.contributor.author | Varadkar, S | |
| dc.contributor.author | McMorrow, S | |
| dc.contributor.author | Fanning, R | |
| dc.contributor.author | Flynn, C M | |
| dc.contributor.author | O' Riordan, J M | |
| dc.contributor.author | Byrne, B M | |
| dc.date.accessioned | 2013-02-19T13:03:48Z | |
| dc.date.available | 2013-02-19T13:03:48Z | |
| dc.date.issued | 2012-10 | |
| dc.identifier.citation | The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. 2012, 22 (5):344-9 Transfus Med | en_GB |
| dc.identifier.issn | 1365-3148 | |
| dc.identifier.pmid | 22994449 | |
| dc.identifier.doi | 10.1111/j.1365-3148.2012.01178.x | |
| dc.identifier.uri | http://hdl.handle.net/10147/269761 | |
| dc.description.abstract | Fibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Transfusion medicine (Oxford, England) | en_GB |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Blood Loss, Surgical | |
| dc.subject.mesh | Coagulants | |
| dc.subject.mesh | Delivery, Obstetric | |
| dc.subject.mesh | Factor VIII | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Fibrinogen | |
| dc.subject.mesh | Hemorrhage | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Ireland | |
| dc.subject.mesh | Pregnancy | |
| dc.subject.mesh | Prospective Studies | |
| dc.title | The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study. | en_GB |
| dc.type | Article | en |
| dc.contributor.department | Department of Obstetrics and Gynaecology, Coombe Women and Infants University Hospital, Dublin, Ireland. | en_GB |
| dc.identifier.journal | Transfusion medicine (Oxford, England) | en_GB |
| dc.description.province | Leinster | en |
| refterms.dateFOA | 2018-08-23T03:46:10Z | |
| html.description.abstract | Fibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen. |
